Matthew Matasar: Exploring the Future of Bispecific Antibodies in Marginal Zone Lymphoma
Matthew Matasar/ LinkedIn

Matthew Matasar: Exploring the Future of Bispecific Antibodies in Marginal Zone Lymphoma

Matthew Matasar, Division Chief, Blood Disorders at Rutgers Cancer Institute, shared on LinkedIn:

I had the pleasure of working with Elizabeth Brem and MedscapeCME on a program focusing on bispecific antibodies in marginal zone lymphoma.

Definitely an area of needed study and an opportunity for the field!”

Read more.

Other articles about lymphoma on OncoDaily.